NORADRENALINE IN PRETERM INFANTS WITH CARDIOVASCULAR COMPROMISE
John Hunter Childrens Hospital Noradrenaline (NA) is beneficial in the treatment of term newborns with cardiovascular compromise due to sepsis or pulmonary hypertension, but experiences with NA in preterm infants are limited. The aim of this study is to describe the efficacy and safety of NA in preterm infants. Patient records of preterm infants < =32 weeks' gestation admitted to two hospitals between 2004 and 2015 and who received NA were reviewed for perinatal morbidities and mortality. Clinical details were collected at the time of NA use, and response on blood pressure, perfusion and oxygenation was documented as well as possible side effects. Forty-eight infants with primary diagnoses of sepsis (63 %) and pulmonary hypertension (23 %) received NA. Normotension was achieved at a median of 1 h in all but one infant at a median dose of 0.5 mcg/kg/min. Infants who died (46 %) were of younger gestational age and had worse cardiovascular function at start of NA compared to infants who survived. Tachycardia was common (31 %), but no additional effects were found on kidney or liver function. Background: Both pain and common pharmacological analgesics may adversely affect newborn neurodevelopmental outcomes. We investigated the feasibility and safety of magnetic acupuncture (MA) as an adjunctive analgesic for heel pricks in newborn infants.
Conclusion
Method: After parental consent, infants requiring heel pricks for blood collection were randomised to either MA (n = 21) or placebo (P) (n = 19) between 15th Aug -10th Nov 2016. Five MA or placebo stickers were placed on auricular acupuncture sites on each ear for 3 days by an unblinded investigator. Pain responses were assessed with the Premature Infant Pain Profile (PIPP) by blinded clinicians 15 minutes before and after and during each heel prick. The study was registered in the Australian and New Zealand Clinical Trial Registry (ACTRN1261 6001229460).
Results: Infants were similar in birth weight (MA:2303 g, P:2104 g) and age at heel prick (MA:5.3, P:4.5 days). Mean (SD) PIPP scores were similar before (MA:1.7(1.4), P:2.1(1.9)) and after (MA:1.6(1.4), P: 2.1(1.7)) heel pricks but were lower in MA infants during heel pricks (MA:5.9(3.7) v P: 8.3(4.7), p = 0.04). One-way ANCOVA modelling demonstrated a significant effect of MA on heel prick PIPP scores even after controlling for analgesia (p = 0.043, eta 2 = 0.07). No differences were noted in heart rate, SpO 2 or incidence of adverse effects (e.g. local skin reactions, sticker displacement). Conclusions: Auricular MA is feasible in neonates and may reduce PIPP scores during common procedures like heel pricks. Further studies are required to determine the impact of MA on other painful procedures and on neurodevelopmental outcomes. Background: Even though hypoglycaemia is the most common metabolic abnormality in neonates, its definition remains controversial. Our new hypoglycaemia screening pathway defined hypoglycaemia as a plasma glucose concentration of less than 2.9 mmol/L in the first 48 hours of life (J Ped 2015; 167:238-245) .
AUDIT OF THE BLOOD SUGAR PROFILES OF AT-RISK
Method: Blood glucose profiles of infants at-risk of hypoglycaemia born during August to November 2016 were analysed.
Infants recruited into the hypoglycaemia pathway included latepreterms, small or large for gestational age (SGA/LGA), infants of diabetic mother (IDM), and those born to mothers with a BMI >33 kg/m2. The pathway involves enteral milk feeds within 2 hours of birth and blood sugar monitoring at 2, 6, 12, 18, 24 and 36 hours of life.
Results: Seventy infants, including 17(22%) IDM, 11(14%) SGA, 21(28%) born to obese mothers with raised BMI and 6 (8%) late-preterm infants were studied prospectively. Combined risk factors were present in 18 infants and one of them developed hypoglycaemia, managed with buccal glucose gel and top up feeds. Eleven (14%) infants with single risk factors developed hypoglycaemia, 10 required buccal glucose gel and additional milk feeds. Overall, only one infant (0.7%) needed admission to the special care nursery (SCN) for parenteral glucose with a maximum glucose infusion rate of 5.6 mg/kg/min.
Conclusions: Early enteral feeding of infants at-risk of hypoglycaemia ensures smooth post-natal glucose transition in early life. We observed a low incidence of hypoglycaemia requiring parental glucose in our cohort. Administration of glucose gel and optimization of enteral milk feeds in infants with hypoglycaemia precluded admission to SCN for parenteral glucose. Background: Bronchopulmonary dysplasia (BPD) is a severe chronic lung disease of preterm infants with grave short-and long-term consequences. To date there is no effective and safe therapy in clinical use. We recently showed that prophylactic treatment with interleukin 1 receptor antagonist (IL-1Ra) prevents development of murine BPD. We assess whether delayed onset and higher dose of (IL-1Ra) treatment, and a second antiinflammatory agent, protein C (PC), prevent BPD.
Method: Murine BPD was induced by perinatal inflammation and hyperoxia. Pups received daily injections of vehicle, 1200 IU/ kg PC, 10 mg/kg IL?1Ra (early or late onset) or 100 mg/kg IL-1Ra.
Results: 10 mg/kg IL-1Ra prevented BPD more effectively than treatment with 100 mg/kg IL-1Ra, but only when treatment commenced at day 1 of life (compared to controls 28% reduction in alveolar size, 34% increase in alveolar number and 21% increase in surface area-to-volume ratio). There was a nonsignificant trend to reduced BPD severity with PC (up to 18% increase in alveolar number and lung surface area, 18% decrease in alveolar size). IL?1?, IL-1Ra, soluble intercellular adhesion molecule (sICAM)-1, IL-6 and macrophage inflammatory protein (MIP)-2 emerged as main targets in the PC-regulated pulmonary immune response (downregulation by up to 89?fold).
Conclusions: Our data indicate that prophylactic treatment with low-dose IL-1Ra is necessary to prevent BPD. Moreover, as IL-1Ra and PC employ different mechanisms of action, combined
